# PZENA EMERGING MARKETS VALUE FUND

#### **PORTFOLIO MANAGERS**



Rakesh Bordia With Pzena since 2007 In Industry since 1998



Caroline Cai, CFA With Pzena since 2004 In Industry since 1998



Allison Fisch With Pzena since 2001 In Industry since 1999



Akhil Subramanian With Pzena since 2017 In Industry since 2008

#### **FUND FACTS**

Responsible Entity	Equity Trustees Limited
Inception Date	26 October 2016
APIR*	ETL0483AU
ARSN*	613 119 681
Base Currency	AUD
Minimum Investment Amount	A\$25,000
Fund AUM	A\$159.3 Million
Management Expense Ratio*	0.95%
Liquidity	Daily
Benchmark Index	MSCI Emerging Markets, net in A\$
Investment Universe	1,000 largest companies from non-developed countries
# of Positions	Generally 30-60
Buy/Sell Spread	0.50%/0.50%

Registered for distribution in Australia and New Zealand \* Displayed for wholesale share class.

### **ENQUIRIES**

#### Paul Whymper-Williams

Director of Business Development and Client Services +61 (0)421 915 366 whymper-williams@pzena.com

#### John Jardim

Head of Australia & New Zealand +61 (0)419 519 852 jardim@pzena.com


For unit pricing visit: www.eqt.com.au/insto

PERFORMANCE SUMMARY - AUD			ANNUALISED		
	QTD 2024	One Years	Three Years	Five Year	Since Inception 26 Oct 2016
Pzena Emerging Markets Value Fund (gross of fees)	7.9%	16.6%	12.1%	11.5%	11.7%
Pzena Emerging Markets Value Fund (net of fees)	8.1%	16.0%	11.4%	10.6%	10.6%
MSCI Emerging Markets Index	4.7%	17.3%	1.8%	5.2%	7.1%
MSCI Emerging Markets Value Index	4.1%	15.7%	4.7%	5.3%	6.7%


The above performance numbers are based on unaudited financial statements. The MSCI Emerging Markets Index is used as a benchmark to indicate the investment environment existing during the time periods shown in this report. The MSCI Emerging Markets Index is a free float-adjusted market capitalization index that is designed to measure equity market performance of emerging markets, and provides equity returns including dividends net of withholding tax rates as calculated by MSCI. The MSCI Emerging Markets Index cannot be invested in directly. Pzena Emerging Markets Value Fund return reflects month end valuations as at the last business day of each month and the Since Inception returns are annualised. Past performance is not necessarily an indicator of future performance.

PORTFOLIO CHARACTERISTICS				
	Emerging Markets Value Fund	MSCI Emerging Markets® Index		
Price / Earnings (1-Year Forecast)	8.7x	13.5x		
Price / Book	1.1x	1.9x		
Dividend Yield	4.2	2.5		
Median Market Cap (A\$B)	\$22.3	\$11.7		
Weighted Average Market Cap (A\$B)	\$128.0	\$216.4		
Active Share	80.8	-		
Number of Stocks	56	1,277		

Source: MSCI Emerging Markets Index, Pzena Analysis



Region weights adjusted for cash - may appear higher than actual.



Sector weights adjusted for cash - may appear higher than actual. Numbers may not add due to rounding.



### PZENA EMERGING MARKETS **VALUE FUND**

#### **TOP 10 HOLDINGS**

TAIWAN SEMICONDUCTOR MFG	4.8%
ALIBABA GROUP HOLDING LIMITED	4.3%
CHINA OVERSEAS LAND & INVESTMENT LTD	3.6%
SAMSUNG ELECTRONICS CO. LTD.	3.3%
AMBEV SA	3.2%
COGNIZANT TECHNOLOGY SOLUTIONS CORP	3.1%
BAIDU INC.	2.9%
WH GROUP LTD. (HK)	2.9%
WEICHAI POWER CO. LTD.	2.9%
HAIER SMART HOME CO. LTD.	2.9%
Total	33.9%

Numbers may not add due to rounding.

#### **INVESTMENT PROCESS**

- Universe: 1000 largest companies from non-developed countries
- Fundamental research conducted on companies considered the most undervalued based on price relative to normalized earnings
- Co-Portfolio Managers construct a portfolio of deeply undervalued businesses requiring unanimous consent



#### **PLATFORMS**

**AMP** BT Panorama Hub24 Macquarie Mason Stevens Netwealth Praemium







The rating issued 05/2024 is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit lonsec.com.au for ratings information and to access the full report. © 2024 Lonsec. All rights reserved.

The Genium rating (assigned June 2024) presented in this document is issued by Genium Investment Partners Pty Ltd ABN 13 165 0.99 785, which is a Corporate Authorised Representative of Genium Advisory Services Pty Ltd ABN 94 304 403 582, AFSL 246580. The Rating is limited to "General Advice" (s766B Corporations Act 2001 (Cth)) and has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without notice. Past performance information is for illustrative purposes only and is not indicative of future performance. It is not a recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision in relation to this financial product(s). Genium receives a fee from the Fund Manager for researching and rating the product(s). Visit Geniumip.com.au for information regarding Genium's Ratings methodology.

Pzena Investment Management, LLC ("PIM") received the 'Highly Commended' designation for the 2024 Financial Newswire/ SOM Research Fund Manager of the Year Awards for the Pzena Ernerging Markets Value Wholesale Fund. This award was based on the time period 31 May 2021 - 31 May 2024. PIM did not provide any compensation in connection with obtaining this award.

Pzena Investment Management, LLC was awarded 'Emerging Manager of the Year' by Money Management Australia in partnership with Lonsec for the year 2023. PIM did not provide any compensation in connection with obtaining this award. PIM did pay a standard rating fee to have its funds rated by Lonsec





nerging Markets Equiti

Genium

#### PORTFOLIO QUARTERLY COMMENTARY - Q3 2024

After a relatively quiet July and August, emerging markets rallied in the final days of September, as the Chinese government announced several monetary and fiscal stimulus measures. Our Emerging Markets Select Value portfolio closed the quarter up, benefitting from its overweight China/HK exposure, outperforming its MSCI EM benchmark.

The MSCI Emerging Markets Index returned 4.7% for the guarter and its Value counterpart, 4.1%. The Fund outperformed in the quarter, posting an 8.6% return. Top performing sectors were consumer discretionary and health care, while information technology and energy posted negative returns in the quarter.

Within our portfolio, by sector, financials led the gains, while the portfolio benefitted from its underweight in information technology. The top individual performer, Alibaba, reported decent Q2 results, as the tech giant continues to invest in its ecommerce platform, which is helping to stabilize its market share. WH Group, the world's largest pork producer, participated in the Chinese market rally, and property developer China Overseas Land and Investment benefitted from some of the announced policy measures in China. Seven of the top ten contributors were Chinese.

The health care underweight was the key relative detracting factor at the sector level. Individual stock detractors included Kazakhstan-based fintech Kaspi which was the subject of a short report in the quarter, negatively impacting shares. Our research indicates that this report is misleading and misrepresents the business, and we continue to believe in Kaspi's dominant franchises in payments, ecommerce, and banking. South African chemical company Sasol continues to work through a challenging demand backdrop and operational issues in its mines. Hyundai Mobis was also a detractor, reversing some of last quarter's gains after it reported a mixed

set of 2Q results; with, electrification continuing to negatively impact the auto business, which is still loss-making.

We initiated a position in Gedeon Richter, a Hungarian pharmaceutical company that derives the bulk of its profitability from one drug - Vraylar - which is slated to lose exclusivity in 2029. We believe management is prudently allocating capital to the non-Vraylar businesses, and the shares trade at an attractive multiple on the ex-Vraylar earnings. We added to Samsung Electronics, WH Group, and Brazilian bank Itau Unibanco, on valuation. To fund these purchases, we exited Chinese auto manufacturer Brilliance, Indian pharma, Aurobindo and Trip.com. and reduced the portfolio's exposure to electronics assembler Hon Hai, Indian non-bank financial company Shriram, and Korean lender Shinhan.

Even after the Chinese rally, we believe valuations continue to be attractive and we remain overweight China, with Brazil and Korea also making up a sizable portion of the portfolio.



## PZENA EMERGING MARKETS VALUE FUND

#### **DISCLAIMERS**

This document has been prepared and issued by Pzena Investment Management, LLC (ARBN 108 743 415), a limited liability company ("Pzena"). Pzena is regulated by the Securities and Exchange Commission (SEC) under U.S. laws, which differ from Australian laws. Pzena is exempt from the requirement to hold an Australian financial services license in Australia in accordance with ASIC Class Order CO 03/1100 and the transitional relief under ASIC Corporations (Repeal and Transitional) Instrument 2016/396, extended through 31 March 2026 by ASIC Corporations (Amendment) Instrument 2024/497. Pzena offers financial services in Australia to 'wholesale clients' only pursuant to that exemption. This document is not intended to be distributed or passed on, directly or indirectly, to any other class of persons in Australia.

Equity Trustees Limited ("Equity Trustees") (ABN 46 004 031 298), AFSL 240975, is the Responsible Entity for the Pzena Emerging Markets Value Fund ("the Fund"). Equity Trustees is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a publicly listed company on the Australian Securities Exchange (ASX: EQT). The Investment Manager for the Fund is Pzena Investment Management, LLC (ARBN 108 743 415) ("Pzena"). This publication has been prepared by Pzena to provide you with general information only. In preparing this information, we did not take into account the investment objectives, financial situation or particular needs of any particular person. It is not intended to take the place of professional advice and you should not take action on specific issues in reliance on this information. Neither Equity Trustees, Pzena nor any of their related parties, their employees or directors, provide any warranty of accuracy or reliability in relation to such information or accept any liability to any person who relies on it. Neither Equity Trustees nor Pzena are registered as financial service providers in New Zealand, and neither of them is able to provide financial advice to any person in New Zealand who is not a 'wholesale investor' within the meaning of clauses 3(2) of Schedule 1 of the FMCA. Past performance should not be taken as an indicator of future performance. You should obtain a copy of the Product Disclosure Statement before making a decision about whether to invest in this product. The Fund's Target Market Determination is available here https://www.eqt.com.au/insto/. A Target Market Determination is a document which is required to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where the Target Market Determination for this financial product may need to be reviewed.

In New Zealand, any offer of this Wholesale Class of the Fund is limited to 'wholesale investors' within the meaning of clause 3(2) of Schedule 1 of the Financial Markets Conduct Act 2013 ('FMCA'). This document is not to be treated as an offer, and is not capable of acceptance by, any person in New Zealand who is not a Wholesale Investor.

While information contained in this document has been prepared with all reasonable care, no responsibility or liability is accepted by Pzena for any errors or omissions or misstatements however caused. The information contained herein is not an indication of future performance of the Fund. Information provided herein is general information only and does not take account of your personal objectives, financial situation or needs. Accordingly, you should obtain financial advice to ascertain the suitability of our products for their personal financial needs and circumstances. You should also consider information in the Product Disclosure Statement ("PDS") and Reference Guide before making a decision about investing in the Fund.

In accordance with broadly accepted Australian Unit Trust practice, in early July, Pzena's unit trusts will undergo a 'blackout period' during which time any investor applications/ redemptions will be delayed. While investor transactions will continue to be processed, the trusts must halt securities trading for the duration of the blackout period, which may impact performance based on the relative value of the trust's cash. Pricing for each valuation period during the blackout will be calculated following the trust administrator's completion of end of fiscal year distribution calculations in mid-July. At the conclusion of the blackout period daily unit pricing will resume, and the application/redemption process will return to normal.

Ratings are not the only factor to be taken into account when deciding whether to invest in a financial product. Ratings can change in the future. Please refer to www.lonsec.com.au for further information about the meaning of the rating and the rating scale.

For further information about the Financial Newswire/SQM Research 'Highly Commended' designation, please refer to www.financialnewswire.com.au/fund-manager-of-the-year-awards-2024/#methodology.

All investments involve risk, including loss of principal. The price of equity securities may rise or fall because of economic or political changes or changes in a company's financial condition, sometimes rapidly or unpredictably. Investments in foreign securities involve political, economic and currency risks, greater volatility and differences in accounting methods. These risks are greater for investments in Emerging Markets. The Fund emphasizes a "value" style of investing, which targets undervalued companies with characteristics for improved valuations. This style of investing is subject to the risk that the valuations never improve or that returns on "value" securities may not move in tandem with the returns on other styles of investing or the stock market in general.

© Pzena Investment Management, LLC, 2024. All rights reserved.